{
  "meta": {
    "id": "test22",
    "title": "PSM-(INICET NOV 2024)",
    "category": "INICET PYQ"
  },
  "questions": [
    {
      "text": "Which is not a part of Anemia Mukt Bharat Programme?",
      "options": [
        {
          "label": "A",
          "text": "6 beneficiaries",
          "correct": false
        },
        {
          "label": "B",
          "text": "6 interventions",
          "correct": false
        },
        {
          "label": "C",
          "text": "6 institutional mechanisms",
          "correct": false
        },
        {
          "label": "D",
          "text": "6 health functionaries",
          "correct": true
        }
      ],
      "correct_answer": "D. 6 health functionaries",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>6 health functionaries The Anemia Mukt Bharat Programme is a national initiative aimed at reducing anemia in India. It employs a 6x6x6 strategy, focusing on six beneficiary groups (children, adolescents, pregnant and lactating women), six interventions (iron supplementation, deworming, behavior change communication, etc.), and six institutional mechanisms for effective implementation.</p>\n<p><strong>Highyeild:</strong></p><p>The Anemia Mukt Bharat program is a comprehensive and multi-pronged approach to address the problem of anemia in India. By focusing on early detection, prevention, and management, the program aims to improve the health and well-being of millions of women and children. Objectives: Reduce prevalence of anemia among pregnant women and children (6-59 months) to less than 5% by 2030. Ensure early detection and management of anemia through screening and testing. Promote preventive measures to address the root causes of anemia. Key interventions: Intensified Iron Folic Acid Supplementation (IFA) program for pregnant women and children. Deworming tablets for children. Behaviour change communication activities to promote dietary diversification and healthy practices. Integration with other health programs such as the National Health Mission (NHM) and the Anganwadi program. Monitoring and evaluation: Regular monitoring of program implementation and coverage. Conduct of anemia surveys to track progress. Evaluation of the impact of the program on anemia prevalence and related outcomes. Key stakeholders: Ministry of Health and Family Welfare (MoHFW) State health departments Implementing agencies such as UNICEF, WHO, and NGOs Communities and beneficiaries</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. 6 beneficiary groups: Children (6-59 months), children (5-9 years), adolescents (10-19 years), pregnant women, lactating women, and women of reproductive age group (15-49 years). Option: B. 6 interventions: Prophylactic Iron Folic Acid Supplementation, Periodic Deworming, Intensified Year-Round Behavior Change Communication, Delayed Cord Clamping, Increased Testing and Treatment of Anemia, and Fortification of Foods. Option: C. 6 institutional mechanisms: A robust institutional mechanism at the national, state, and district levels to ensure effective implementation of the program.</p>\n<p><strong>Table:</strong></p><p>#MANTRA IFA supplementation for different age groups: Age group Iron dose Folic Acid dose Timing Color Remarks Children 6-59 months of age 20 mg Iron 100 mcg Bi weekly Liquid bottle with auto dispenser Children 5-9 years of age 45 mg 400 mcg Weekly Pink color Sugar coated School-going Adolescent Girls and Boys, 10-19 years of age Out-of-school Adolescent Girls, 10-19 years of age 60 mg 500 mcg Weekly Blue color Sugar coated Women of Reproductive Age (non-pregnant, non-lactating) 20-49 years (Under Mission Parivar Vikas) 60 mg 500 mcg Weekly Red color Sugar coated Pregnant Women and Lactating Mothers (of 0-6 months child) 60 mg 500 mcg Daily Red color Sugar coated</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8dfc3f45",
      "audio": ""
    },
    {
      "text": "You have gone to a village for screening where people have diabetes and hypertension. What type of screening is done for family members of these patients who show up in large numbers?",
      "options": [
        {
          "label": "A",
          "text": "Multiphasic screening",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mass screening",
          "correct": false
        },
        {
          "label": "C",
          "text": "High-risk screening",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anonymous screening",
          "correct": false
        }
      ],
      "correct_answer": "C. High-risk screening",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>High-risk screening High-risk screening is conducted for family members of patients with conditions like diabetes and hypertension. Since these individuals are at a higher risk of developing the same conditions due to genetic or environmental factors, screening focuses on identifying those at higher risk rather than screening the entire population. This approach is more efficient and targeted compared to mass or multiphasic screening.</p>\n<p><strong>Highyeild:</strong></p><p>Screening is a process of identifying individuals in a population who are at risk of a particular disease or condition, or who may already have it, but do not yet show symptoms. The goal of screening is to detect diseases at an early stage, when they are more treatable, and to prevent further complications. Mass screening refers to screening the entire population or large groups of people, regardless of their risk factors, to detect certain diseases early. This approach is typically used for conditions with high prevalence and for which early detection leads to better outcomes, such as newborn screening for metabolic disorders. High-risk (or selective/targeted) screening focuses on individuals who are at greater risk of developing a specific disease, such as family members of individuals with hypertension or diabetes. This approach helps in early detection among populations that are more likely to develop the condition, improving resource allocation and targeting high-risk individuals. Multiphasic screening involves testing for multiple diseases or conditions at once, typically using several tests during a single visit. This type of screening is more efficient in terms of time and resources, especially in large populations. It may include screenings for conditions like diabetes, hypertension, and cholesterol levels, all performed simultaneously. Multipurpose screening refers to screening individuals for a variety of health conditions during a single screening event, but the focus is often on addressing different health problems in the same target population. For example, screening a community for a range of chronic diseases such as cardiovascular conditions, diabetes, and cancer in one setting. Opportunistic and case-finding screening occurs when individuals are screened for a condition during a visit for another health problem. It takes advantage of opportunities when patients are already in healthcare settings, such as checking blood pressure or glucose levels during routine checkups. This method is effective for finding cases that may otherwise go unnoticed, especially for chronic conditions.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Multiphasic screening : This involves testing multiple conditions or diseases simultaneously in the general population, often through a series of tests at one time. It is not specifically focused on family members or high-risk groups. Option: B. Mass screening : This refers to screening large populations regardless of their risk status. It aims to detect diseases early in the general population, not focusing on high-risk individuals such as family members of patients with diabetes or hypertension. Option: D. Anonymous screening : This involves screening individuals without requiring personal identifiers, typically used for conditions where confidentiality is paramount, such as in HIV testing. It does not specifically relate to the high-risk screening of family members of individuals with chronic diseases.</p>\n<p><strong>Extraedge:</strong></p><p>Prescriptive Vs Prospective Screening: Prescriptive screening Prospective screening Definition People screened for owns benefits People screened for others benefits Essential purpose Case detection Disease control Request for screening Nonspecific request Special request from authority Eg Neonatal screening Pap smear Urine for sugar Screening of immigrants, HIV screening among sex workers</p>\n<p><strong>Table:</strong></p><p>#MANTRA Types of Screening: Type of Screening Description Target Population Purpose Multiphasic Screening \u25cf       Screening for multiple diseases or conditions during a single visit. \u25cf       General population, often for various conditions. \u25cf       Efficient detection of multiple diseases. Mass Screening \u25cf       Screening the entire population or large groups, regardless of risk. \u25cf       General population. \u25cf       Early detection of high-prevalence diseases. High-risk Screening \u25cf       Screening targeted at individuals with higher risk (e.g., family history). \u25cf       High-risk groups (e.g., family members of patients with chronic diseases). \u25cf       Early detection in those at greater risk. Anonymous Screening \u25cf       Screening where personal identifiers are not used, ensuring confidentiality. \u25cf       Any population, especially for sensitive conditions. \u25cf       Confidential testing for privacy protection.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7207b4b7",
      "audio": ""
    },
    {
      "text": "Which of the following groups is not included in the high-risk core population for HIV transmission?",
      "options": [
        {
          "label": "A",
          "text": "IV drug users",
          "correct": false
        },
        {
          "label": "B",
          "text": "Female sex workers",
          "correct": false
        },
        {
          "label": "C",
          "text": "Men who have sex with men",
          "correct": false
        },
        {
          "label": "D",
          "text": "Long distance truck drivers",
          "correct": true
        }
      ],
      "correct_answer": "D. Long distance truck drivers",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Long distance truck drivers The correct answer is Long distance truck drivers. High-risk core populations for HIV transmission include groups with behaviors that increase the likelihood of exposure, such as IV drug users, female sex workers, and men who have sex with men. These groups are at higher risk due to factors like needle sharing, multiple sexual partners, and unprotected sexual activities. While long distance truck drivers may engage in risky behaviors, they are not generally classified as a core high-risk group for HIV transmission compared to the others.</p>\n<p><strong>Highyeild:</strong></p><p>HIV transmission occurs through several primary routes, with each carrying different risks of transmission depending on the context. Here\u2019s a breakdown with approximate transmission risks: Sexual Transmission : This is the most common route, with about 80-85% of new HIV infections worldwide occurring through sexual contact. The risk of transmission varies: Unprotected vaginal sex has a risk of about 0.1% to 0.2% per act for women and 0.04% to 0.1% for men. Unprotected anal sex carries a higher risk, especially for receptive anal intercourse, with a transmission risk of about 0.5% to 1% per act. Oral sex has a much lower risk, but it is still possible, especially if there are open sores or bleeding gums. The risk is generally less than 0.04% per act. Needle Sharing (Intravenous Drug Use): The risk of HIV transmission through needle sharing is very high, approximately 0.63% to 1.8% per shared needle. This is due to direct blood-to-blood contact, which facilitates the transfer of the virus. Blood Transfusions: Before screening methods were developed, blood transfusions were a major risk factor for HIV transmission. However, the risk has decreased dramatically with modern screening, now being less than 1 in 2 million units of blood transfused in many countries. Mother-to-Child Transmission (MTCT) : If an HIV-positive mother is not receiving treatment, the risk of transmission to the child during pregnancy, childbirth, or breastfeeding can be as high as 25% to 45%. However, with antiretroviral therapy (ART), the risk can be reduced to less than 1%. Other Routes (Occupational Exposure, Contaminated Medical Instruments): The risk of HIV transmission through occupational exposure (e.g., needlestick injuries) is about 0.3%. The risk through contaminated medical instruments, though rare in countries with proper infection control, can also pose a threat if instruments are not sterilized properly.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. IV drug users : IV drug users are at high risk for HIV transmission because sharing needles can directly transmit the virus, making them one of the highest-risk groups. Option: B. Female sex workers : Female sex workers are also at high risk due to their occupation, which often involves multiple sexual partners and unprotected sex, increasing the likelihood of exposure to HIV. Option: C. Men who have sex with men : Men who have sex with men are at a higher risk for HIV due to higher rates of unprotected sex and the potential for exposure during anal intercourse, which has a higher transmission risk for HIV.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "56cffefe",
      "audio": ""
    },
    {
      "text": "All are live vaccines except:",
      "options": [
        {
          "label": "A",
          "text": "Rota Virus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hepatitis B",
          "correct": true
        },
        {
          "label": "C",
          "text": "Measles",
          "correct": false
        },
        {
          "label": "D",
          "text": "Varicella",
          "correct": false
        }
      ],
      "correct_answer": "B. Hepatitis B",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Hepatitis B The Hepatitis B vaccine is not a live vaccine; it is an inactivated (subunit) vaccine made from the recombinant hepatitis B surface antigen. In contrast, Rota Virus, Measles, and Varicella are all live attenuated vaccines, meaning they contain weakened forms of the virus that stimulate the immune system without causing disease. Live vaccines typically require fewer doses, but they are not suitable for individuals with weakened immune systems.</p>\n<p><strong>Highyeild:</strong></p><p>Live Vs Killed Vaccines: Feature Live Vaccines Killed (Inactivated) Vaccines Composition \u25cf       Contain live, weakened forms of the virus or bacteria. \u25cf       Contain killed or inactivated virus or bacteria. Immune Response \u25cf       Stimulate a strong, long-lasting immune response, often with one or two doses. \u25cf       Generally induce a weaker immune response, may require multiple doses. Examples \u25cf       Measles, Mumps, Rubella (MMR), Varicella, Rotavirus, Yellow fever. \u25cf       Hepatitis A, Hepatitis B, Polio (Salk), Influenza (inactivated). Storage \u25cf       May require special storage conditions (e.g., refrigeration or freezing). \u25cf       Generally more stable, can be stored at room temperature or standard refrigeration. Side Effects \u25cf       May cause mild symptoms resembling the disease in rare cases. \u25cf       Less likely to cause side effects, but may require adjuvants to boost the immune response. Safety \u25cf       Safe for most people, but not for those with weakened immune systems (e.g., immunocompromised individuals). \u25cf       Safe for immunocompromised individuals, as they do not contain live organisms. Efficacy \u25cf       Often more effective in providing long-term immunity. \u25cf       May require booster doses for sustained immunity.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Rota Virus : This is a live attenuated vaccine. It contains weakened forms of the rotavirus, which stimulate the immune system to produce immunity without causing disease. Option: C. Measles : This is also a live attenuated vaccine. It contains a weakened form of the measles virus, which replicates in the body to trigger an immune response without causing the disease. Option: D. Varicella : Like the others, the varicella vaccine is a live attenuated vaccine. It contains a weakened form of the varicella-zoster virus, which induces immunity to chickenpox without causing the actual disease.</p>\n<p><strong>Table:</strong></p><p>#MANTRA The Universal Immunization Program (UIP) in India is a comprehensive immunization program implemented by the Government of India to provide vaccination against various preventable diseases. Vaccine Diseases Protected Against Age Group BCG Tuberculosis At birth OPV (Oral Polio Vaccine) Polio Birth, 6 weeks, 10 weeks, 14 weeks, and booster dose at 16-24 months Hepatitis B Hepatitis B Birth, 6 weeks, 10 weeks DTP (Diphtheria, Tetanus, Pertussis) Diphtheria, Tetanus, Pertussis 6 weeks, 10 weeks, 14 weeks, and booster doses at 16-24 months and 5 years Hib (Haemophilus influenzae type b) Haemophilus influenzae type b 6 weeks, 10 weeks, 14 weeks, and booster dose at 16-24 months Rotavirus Rotavirus diarrhea 6 weeks, 10 weeks PCV (Pneumococcal Conjugate Vaccine) Pneumonia, Meningitis 6 weeks, 10 weeks, 14 weeks, and booster dose at 16-24 months Measles Measles 9 months Rubella Rubella 9 months JE (Japanese Encephalitis) Japanese Encephalitis At 9 months in endemic areas DTP Booster Diphtheria, Tetanus, Pertussis 16-24 months OPV Booster Polio 16-24 months Measles-Rubella (MR) Measles, Rubella 16-24 months Td (Tetanus, diphtheria) Tetanus, Diphtheria 5 years TT (Tetanus Toxoid) Tetanus 10 years (for females) HPV (Human Papillomavirus) Cervical Cancer Administered to adolescent girls in 2 doses between 9-14 years</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fb5e483b",
      "audio": ""
    },
    {
      "text": "Which of the following is not a cold sterilisation technique?",
      "options": [
        {
          "label": "A",
          "text": "Plasma sterilization",
          "correct": false
        },
        {
          "label": "B",
          "text": "UV radiation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Gamma radiation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Autoclave",
          "correct": true
        }
      ],
      "correct_answer": "D. Autoclave",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Autoclave The autoclave is not a cold sterilization technique; it uses high-pressure steam to sterilize equipment, involving heat. In contrast, plasma sterilization, UV radiation, and gamma radiation are all cold sterilization methods, as they sterilize without the use of heat. Plasma sterilization uses low-temperature plasma, UV radiation utilizes ultraviolet light, and gamma radiation employs ionizing radiation, all effectively sterilizing materials at lower temperatures.</p>\n<p><strong>Highyeild:</strong></p><p>Sterilization is a process that eliminates or kills all forms of microbial life, including bacteria, viruses, fungi, and spores, from a surface or substance. It is an essential procedure in healthcare settings to prevent infections and maintain hygiene standards, particularly for surgical instruments, medical devices, and laboratory equipment. There are two primary categories of sterilization: heat-based and cold or chemical-based methods. Heat-based sterilization includes methods such as autoclaving, which uses high-pressure steam at temperatures of around 121\u00b0C to 134\u00b0C. This method is effective for most medical tools, as it destroys microorganisms by denaturing their proteins. Another method is dry heat sterilization, which uses hot air at higher temperatures (160\u00b0C to 180\u00b0C) to destroy pathogens by oxidation. Cold sterilization techniques , on the other hand, do not involve heat. Methods like gamma radiation use ionizing radiation to sterilize items, making it suitable for heat-sensitive materials like plastics. UV radiation sterilizes by damaging the DNA of microorganisms, rendering them incapable of replication. Plasma sterilization employs ionized gas (plasma) at low temperatures, offering a safe alternative for heat-sensitive medical equipment. In addition to these methods, chemical sterilization involves the use of chemical agents, such as ethylene oxide gas or hydrogen peroxide vapor, to sterilize equipment without heat. These chemicals are effective in killing microorganisms but require careful handling due to their toxicity and potential for harmful residues.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Plasma sterilization : This involves the use of low-temperature plasma to sterilize equipment, making it a cold sterilization method. Option: B. UV radiation : Ultraviolet light is used to kill or inactivate microorganisms without the use of heat, making it a cold sterilization technique. Option: C. Gamma radiation : This uses ionizing radiation to sterilize medical equipment and is also considered a cold sterilization method, as it doesn\u2019t involve high temperatures.</p>\n<p><strong>Extraedge:</strong></p><p>Spaulding\u2019s Classification:</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8268ea53",
      "audio": ""
    },
    {
      "text": "ICER is a unit for which of the following economical analysis?",
      "options": [
        {
          "label": "A",
          "text": "Cost Effectiveness",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cost Benefit",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cost Utility",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cost Margin",
          "correct": false
        }
      ],
      "correct_answer": "A. Cost Effectiveness",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Cost Effectiveness ICER stands for Incremental Cost-Effectiveness Ratio, which is a key metric used in Cost-Effectiveness Analysis (CEA). It compares the relative costs and outcomes (typically measured in terms of health benefits, such as quality-adjusted life years or life years gained) of different interventions. The ICER is calculated by dividing the difference in cost between two alternatives by the difference in their effectiveness.</p>\n<p><strong>Highyeild:</strong></p><p>Cost-Effectiveness Analysis (CEA) is an economic evaluation method used to compare the costs and health outcomes of different interventions. It is particularly useful in healthcare to assess the value of medical treatments or programs. The results are typically expressed as an Incremental Cost-Effectiveness Ratio (ICER), which calculates the cost per additional unit of health outcome (e.g., quality-adjusted life year or life years gained). CEA allows policymakers to identify the most cost-effective interventions and allocate resources efficiently, especially when resources are limited.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. Cost Benefit Analysis (CBA) involves comparing the costs and benefits of an intervention, usually in monetary terms, and does not use ICER. Option: C. Cost Utility Analysis (CUA) is a specific form of CEA that uses utility measures, like Quality-Adjusted Life Years (QALYs), but does not primarily focus on ICER. Option: D. Cost Margin is not a term used in economic evaluations related to healthcare interventions.</p>\n<p><strong>Table:</strong></p><p>#MANTRA Technique Key Characteristics Cost-Benefit Analysis (CBA) \u25cf       Measures both costs and benefits in monetary terms. Allows comparison of projects with different types of outcomes. \u25cf       Often used for large-scale projects or policy decisions. Can be challenging to accurately monetize intangible benefits. Cost-Effectiveness Analysis (CEA) \u25cf       Compares the costs of different interventions to achieve a specific health outcome. Outcomes are measured in natural units (e.g., lives saved, years of life gained). \u25cf       Useful for comparing alternative interventions within a specific disease area. Does not provide information on the overall value of an intervention. Cost-Utility Analysis (CUA) \u25cf       Extends CEA by incorporating quality of life into the analysis. Outcomes are measured in quality-adjusted life years (QALYs). \u25cf       Allows for comparison of interventions with different types of health outcomes. Requires complex methods for assigning QALY weights. Cost-Minimization Analysis (CMA) \u25cf       Identifies the least costly intervention among those with equivalent outcomes. Assumes that the outcomes of the interventions are equally effective. \u25cf       Often used for generic drug substitution or alternative treatment strategies. Limited in scope as it only considers costs.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "27e3c332",
      "audio": ""
    },
    {
      "text": "Universal health coverage (UHC) means that all people and communities receive the quality health services they need, without financial hardship. Which of the following are the challenges to implementing UHC?",
      "options": [
        {
          "label": "A",
          "text": "Inequalities in the distribution, adequate support and access to quality assured products only in low-income setting",
          "correct": true
        },
        {
          "label": "B",
          "text": "The purpose of UHC is to find a balance between countries' income, health provision and financial burden",
          "correct": false
        },
        {
          "label": "C",
          "text": "To provide healthcare to everyone regardless of the countries' income",
          "correct": false
        },
        {
          "label": "D",
          "text": "UHC only deals with the financial aspect of health and cannot cover health provision to all.",
          "correct": false
        }
      ],
      "correct_answer": "A. Inequalities in the distribution, adequate support and access to quality assured products only in low-income setting",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Inequalities in the distribution, adequate support and access to quality assured products only in low-income setting This option highlights a significant challenge in implementing UHC, particularly in low-income settings. It emphasizes the issue of uneven distribution of resources, inadequate support systems, and limited access to quality healthcare products, which can hinder the realization of UHC goals.</p>\n<p><strong>Highyeild:</strong></p><p>Universal Health Coverage (UHC) is a comprehensive health system goal aimed at ensuring that all people, regardless of their economic status, social position, or geographic location, can access the health services they need. UHC is not just about providing health services, but also about ensuring these services are affordable, of high quality, and accessible to everyone without causing financial hardship. Elements of UHC include: Access to Essential Health Services : This encompasses a range of services from prevention (vaccinations, health education), diagnosis, treatment, rehabilitation, and palliative care. The services must cover the most prevalent health needs, including maternal and child health, communicable and non-communicable diseases, mental health, and emergency care. Financial Protection: A critical aspect of UHC is protecting individuals from the financial burden of healthcare. This includes mechanisms such as insurance schemes, public funding, or other financial protections that minimize out-of-pocket expenses and reduce the risk of falling into poverty due to health costs. Equity: UHC aims to ensure that no one is left behind. This involves addressing disparities in access to healthcare services, particularly for disadvantaged or vulnerable groups such as rural populations, minorities, people with disabilities, and the poor. Quality of Care: Access to services alone is not sufficient; the services must be of adequate quality. This requires investing in trained healthcare professionals, medical technology, infrastructure, and continuous improvement of health systems. Sustainable Financing: Achieving UHC requires sustained financial investments. Countries need to adopt appropriate health financing models, which may include progressive taxes, pooled funds, or social health insurance, to ensure that resources are available and distributed equitably. Health System Strengthening: UHC requires robust health systems that include well-equipped healthcare facilities, a skilled workforce, an efficient supply chain for medicines, and strong governance. It also requires integration across various levels of care, from primary healthcare to specialized services.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. The purpose of UHC is to find a balance between countries' income, health provision and financial burden: While this is a consideration in UHC implementation, it's not the primary problem. The goal is to ensure universal access to quality healthcare, regardless of income levels. Option: C. To provide healthcare to everyone regardless of the countries' income: This is a core principle of UHC. The challenge lies in the practical implementation of this principle, especially in resource-constrained settings. Option: D. UHC only deals with the financial aspect of health and cannot cover health provision to all: UHC encompasses both financial and service delivery aspects of healthcare. It aims to ensure that everyone has access to the necessary health services, not just affordability.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "291ef724",
      "audio": ""
    },
    {
      "text": "Which of the following is the best study design as per hierarchy of evidence?",
      "options": [
        {
          "label": "A",
          "text": "Meta analysis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Case control study",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cohort study",
          "correct": false
        },
        {
          "label": "D",
          "text": "Large RCT",
          "correct": false
        }
      ],
      "correct_answer": "A. Meta analysis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Meta analysis The best study design as per the hierarchy of evidence is meta-analysis because it combines data from multiple high-quality studies, providing a comprehensive and precise estimate of effects. It ranks higher than randomized controlled trials (RCTs), which are strong individual studies but don't synthesize broader evidence. Cohort and case-control studies are observational, making them more prone to bias and lower in the evidence hierarchy.</p>\n<p><strong>Highyeild:</strong></p><p>A meta-analysis is a statistical technique used to combine the results of multiple independent studies on the same topic to derive a more precise and comprehensive understanding of an intervention, treatment, or exposure. It is considered the highest level of evidence in the hierarchy because it synthesizes data from well-conducted studies, typically randomized controlled trials (RCTs), to reduce variability and improve the reliability of conclusions. The process of conducting a meta-analysis involves several steps. First, a systematic review is performed to identify all relevant studies on a specific question or hypothesis. Studies are selected based on predefined inclusion and exclusion criteria to ensure consistency and minimize bias. Next, data from the studies are pooled and analyzed using statistical methods, such as calculating weighted averages, odds ratios, or effect sizes. This approach increases statistical power and helps detect effects that individual studies might not identify due to limited sample sizes. Meta-analyses also include tests for heterogeneity, which evaluate whether the included studies are similar enough in terms of population, methods, and outcomes to justify pooling their results. When heterogeneity is high, subgroup analyses or sensitivity analyses may be performed to explore the sources of variation. A meta-analysis often uses visual tools like forest plots to present the results, showing the combined effect estimate alongside individual study results. Despite its strengths, a meta-analysis has limitations. Its validity depends on the quality of the included studies\u2014poor-quality or biased studies can lead to misleading conclusions. Additionally, publication bias, where studies with positive results are more likely to be published, can skew findings. Proper methods, such as funnel plots, are used to assess and mitigate such biases.</p>\n<p><strong>Random:</strong></p><p>Explanation for other options: - Option: B. Case-Control Study : It is retrospective and prone to recall and selection bias, providing weaker evidence compared to prospective or randomized studies. Option: C. Cohort Study : Though stronger than case-control studies, it is observational and cannot establish causality due to potential confounding factors. Option: D. Large RCT : While a strong design, it represents findings from a single study, which may not account for variability or generalizability. Meta-analysis, by combining data from multiple RCTs, provides more robust and comprehensive evidence.</p>\n<p><strong>Extraedge:</strong></p><p>A forest plot visually summarizes the results of multiple studies in a meta-analysis. Each study is represented by a line (confidence interval) and a square (effect size), where larger squares indicate greater study weight. The vertical line is the null line (e.g., no effect), and results to the left or right suggest benefit or harm, respectively. At the bottom, a diamond represents the pooled effect size, with its width showing the confidence interval. It highlights study variability, overall trends, and the precision of combined findings, aiding in interpreting meta-analysis results.</p>\n<p><strong>Table:</strong></p><p>#MANTRA Cohort Study Case-Control Study Ecological Study Descriptive Study Study Type \u25cf       Observational, Analytic \u25cf       Observational, Analytic \u25cf       Observational, Descriptive \u25cf       Observational, Descriptive Goal \u25cf       Identify associations between exposure and outcome \u25cf       Investigate risk factors for an outcome \u25cf       Describe patterns and trends in populations \u25cf       Describe characteristics of a population Design \u25cf       Follow a group of exposed and unexposed individuals over time to observe incident outcomes \u25cf       Compare individuals with the outcome (cases) to a group without the outcome (controls) \u25cf       Analyze aggregate data (e.g., rates) of groups or regions over time or space \u25cf       Observe and quantify variables in a single point in time Exposure & Outcome \u25cf       Measured before the outcome occurs \u25cf       Measured after the outcome occurs \u25cf       Exposure data not typically available \u25cf       No specific outcome of interest Parameters Calculated \u25cf       Incidence rates, relative risk, hazard ratios, attributable risk \u25cf       Odds ratios, prevalence ratios \u25cf       Correlation coefficients, standardized rates, ecological regression \u25cf       Means, proportions, frequencies, measures of variability (SD, range) Strengths \u25cf       Strong control for confounding variables, can study rare diseases \u25cf       Efficient and cost-effective \u25cf       Can analyze large populations quickly \u25cf       Simple and straightforward Weaknesses \u25cf       Time-consuming and expensive, potential for loss to follow-up \u25cf       Recall bias, selection bias, may not be suitable for rare diseases \u25cf       Ecological fallacy, limited ability to identify individual risk factors \u25cf       Limited to observation, cannot establish causality</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "250ba014",
      "audio": ""
    },
    {
      "text": "A student went on a trip to Jaisalmer, where the temp was 40 degrees, and relative humidity was 20%. What will the mechanism of heat loss in this case be?",
      "options": [
        {
          "label": "A",
          "text": "Evaporation",
          "correct": true
        },
        {
          "label": "B",
          "text": "Radiation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Conduction with air",
          "correct": false
        },
        {
          "label": "D",
          "text": "Conduction with objects",
          "correct": false
        }
      ],
      "correct_answer": "A. Evaporation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Evaporation In Jaisalmer, with a temperature of 40\u00b0C and relative humidity of 20%, the primary mechanism of heat loss would be evaporation. Low humidity allows for more efficient evaporation of sweat from the skin, helping to cool the body. This process becomes the most effective in hot, dry conditions, as the air can absorb moisture, enhancing the body's natural cooling mechanism.</p>\n<p><strong>Highyeild:</strong></p><p>The human body loses heat through four primary mechanisms: radiation, conduction, convection, and evaporation . Radiation involves the emission of infrared radiation from the body to the surrounding environment. The amount of heat lost by radiation depends on the temperature difference between the body and the surroundings. In cooler environments, radiation is a significant cooling mechanism, but in hot conditions, such as 40\u00b0C, the temperature gradient between the body and the surrounding air becomes minimal, reducing the effectiveness of radiation as a cooling mechanism. Conduction is the transfer of heat through direct contact with another material. For example, when the body comes into contact with cooler objects, heat is transferred from the body to the object. However, air is a poor conductor of heat, and when the surrounding environment is hot, conduction is not effective in cooling the body. In such conditions, the body may even gain heat from the surrounding environment, further impeding heat loss. Convection occurs when heat is transferred through the movement of air or water around the body. As the body loses heat, the surrounding air becomes warmer and rises, allowing cooler air to take its place. In windy or cool environments, convection is an effective cooling mechanism. However, in hot, still air, such as in desert conditions, convection is not as effective because the surrounding air is already warm and lacks the capacity to absorb additional heat from the body. The most effective heat loss mechanism in hot and dry conditions is evaporation . When sweat evaporates from the skin, it absorbs heat from the body and carries it away, cooling the body. This process depends on the humidity of the environment\u2014low humidity allows for more efficient evaporation because the air can absorb more moisture. In areas with low humidity, such as deserts, evaporation is enhanced, making it the primary mechanism for heat loss in extreme heat.</p>\n<p><strong>Random:</strong></p><p>Explanation for other options: - Option: B. Radiation : In hot environments, the body radiates heat to the surrounding air, but when the air temperature is high (40\u00b0C), radiation is not effective because there\u2019s little temperature difference between the body and the environment. Option: C. Conduction with air : Conduction relies on direct contact for heat transfer. With air being a poor conductor of heat, it is not an efficient way for the body to lose heat, especially in hot conditions. Option: D. Conduction with objects : For this to be effective, the body would need to be in contact with cooler objects. Since the temperature in Jaisalmer is 40\u00b0C, objects in contact with the body would also be hot, limiting heat transfer through conduction.</p>\n<p><strong>Extraedge:</strong></p><p>Heat Stress Index: HSI Effect of 8-h exposure -20 Mild cold strain (e.g., recovery from heat exposure) 0 No thermal strain 10-30 Mild to moderate heat strain. Little effect on physical work but possible effect on skilled work 40-60 Severe heat strain, involving threat to health unless physically fit. Acclimatization required 70-90 Very severe heat strain. Personnel should be selected by medical examination. Ensure adequate water and salt intake 100 Maximum strain tolerated daily by fit acclimatized young men Over 100 Exposure time limited by rise in deep body temperature</p>\n<p><strong>Table:</strong></p><p>#MANTRA Thermal Comfort Indices:</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e3e3993d",
      "audio": ""
    },
    {
      "text": "Which of the following is not included in SAM?",
      "options": [
        {
          "label": "A",
          "text": "Low weight for height",
          "correct": false
        },
        {
          "label": "B",
          "text": "Low height for age",
          "correct": true
        },
        {
          "label": "C",
          "text": "Pedal edema",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mid upper arm circumference",
          "correct": false
        }
      ],
      "correct_answer": "B. Low height for age",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Low height for age Low height for age (stunting) is not included in the definition of Severe Acute Malnutrition (SAM). SAM is primarily diagnosed using indicators like low weight for height (wasting), pedal edema (swelling due to severe malnutrition), and mid upper arm circumference (MUAC), which helps assess the degree of acute nutritional deficiency. Low height for age reflects long-term malnutrition (stunting), which is a separate concern from acute malnutrition.</p>\n<p><strong>Highyeild:</strong></p><p>Severe Acute Malnutrition (SAM) is a serious condition resulting from a lack of sufficient nutrition, particularly protein and energy, and is characterized by rapid weight loss or failure to gain weight in children. SAM typically manifests in two primary forms: wasting (low weight for height) and kwashiorkor (characterized by edema, especially in the legs and feet, along with a distended abdomen). SAM can also present with marasmus, where there is extreme thinness and muscle wasting without edema. The condition arises from a combination of inadequate dietary intake, poor feeding practices, and frequent infections, leading to a weakened immune system and further nutritional depletion. The primary indicators of SAM include low weight for height, pedal edema, and Mid Upper Arm Circumference (MUAC). MUAC is an easy and effective screening tool, where a circumference of less than 115 mm in children under five years old is considered critical. Wasting, or low weight for height, reflects acute malnutrition, while edema indicates a more severe form of malnutrition, often due to protein deficiency. SAM requires urgent medical attention. Treatment typically involves therapeutic feeding, which includes ready-to-use therapeutic food ( RUTF ) and other nutritional interventions, along with rehydration and infection management. Addressing underlying causes such as infections or poor feeding practices is crucial for recovery. In severe cases, children may need intravenous fluids or hospitalization. If left untreated, SAM can lead to organ failure, growth retardation, immunodeficiency, and even death.</p>\n<p><strong>Random:</strong></p><p>Explanation for other options: - Option: A. Low weight for height : This is a key diagnostic criterion for SAM , specifically indicating wasting , which is a form of acute malnutrition. Children with low weight for height are at risk of severe nutritional deficiencies, and this is a primary indicator of SAM. Option: C. Pedal edema : This is another hallmark of SAM , particularly in conditions like kwashiorkor, where severe protein deficiency causes fluid retention. Pedal edema is a clear sign of severe malnutrition and is included in the diagnosis of SAM. Option: D. Mid upper arm circumference (MUAC) : This is widely used as a screening tool for SAM . A small MUAC indicates severe wasting and malnutrition. It is a quick and effective measurement to assess the nutritional status of children.</p>\n<p><strong>Table:</strong></p><p>#MANTRA Classification of Malnutrition: Classification Index Definition Wasting (Acute malnutrition) Wasting (Acute malnutrition) W/H is normally used as an indicator of current nutritional status. Moderate and severe below minus two SDs (<-2 SD) from median W/H of reference population Stunting (Chronic malnutrition) Height-for-age (H/A) Stunting is linked with long-term factors e.g. chronic malnutrition, mainly protein-energy malnutrition, and frequent illness. Moderate and severe, below minus two SDs from median H/A of reference population (<-2 SD) Underweight (Any protein- energy malnutrition) Weight-for-age (W/A) Reflects acute as well as chronic malnutrition. Moderate and severe</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c081fc20",
      "audio": ""
    },
    {
      "text": "Arrange the steps of experimental study:- Blinding Randomization Defining inclusion and exclusion criteria Statistical analysis Select the correct Answer From the given below Code:",
      "options": [
        {
          "label": "A",
          "text": "3-1-2-4",
          "correct": true
        },
        {
          "label": "B",
          "text": "3-2-1-4",
          "correct": false
        },
        {
          "label": "C",
          "text": "1-2-3-4",
          "correct": false
        },
        {
          "label": "D",
          "text": "4-3-2-1",
          "correct": false
        }
      ],
      "correct_answer": "A. 3-1-2-4",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>3-1-2-4 The correct order is 3-1-2-4 . First, inclusion and exclusion criteria are defined to select the appropriate population. Next, participants are randomized to groups to reduce bias. Blinding is then implemented to ensure unbiased observation of outcomes. Finally, statistical analysis is performed to interpret the data and draw conclusions.</p>\n<p><strong>Highyeild:</strong></p><p>An experimental study design is a powerful research method used to establish cause-and-effect relationships between variables. Unlike observational studies, which merely observe phenomena, experimental studies involve the manipulation of one or more independent variables (e.g., treatments, interventions) to observe their effect on dependent variables (e.g., health outcomes). The ultimate goal is to determine whether changes in the independent variable directly cause changes in the dependent variable. This design allows researchers to draw stronger conclusions about causality, as it controls for confounding factors that could skew results. The study process begins with defining inclusion and exclusion criteria, which are essential for selecting a homogeneous and appropriate study population. These criteria ensure that the study's findings are applicable to the target population and help control for confounding variables. Once the participants are selected, randomization is used to assign them randomly to either an intervention group or a control group. This random allocation ensures that the groups are comparable, reducing selection bias and ensuring that differences between the groups are due to the intervention, rather than pre-existing differences. To minimize bias further, blinding is often employed. Single blinding means participants do not know which group they belong to, while double blinding means both participants and researchers are unaware of group assignments. This helps to eliminate any expectation bias, where participants' or researchers' beliefs about the treatment could influence the outcomes. Blinding is particularly crucial in preventing subconscious influences on data collection or analysis. After the intervention, the study proceeds with data collection and outcome measurement. The data collected are analyzed using various statistical methods to determine whether the observed differences between groups are statistically significant and whether they can be attributed to the intervention. Statistical techniques help account for variability in the data and improve the reliability of the results. The strength of experimental designs lies in their ability to control for confounding variables and isolate the effect of the intervention.</p>\n<p><strong>Random:</strong></p><p>Explanation for other options: - Option: B. 3-2-1-4 : Randomization cannot occur before defining inclusion and exclusion criteria, as the study population must be selected first. Option: C. 1-2-3-4 : Blinding cannot precede randomization because randomization must be done first to assign participants to groups. Option: D. 4-3-2-1 : Statistical analysis is the final step and cannot occur before defining criteria, randomization, and blinding, which are essential for setting up the study.</p>\n<p><strong>Table:</strong></p><p>#MANTRA Epidemiological studies are classified into observational and experimental types. Observational studies, like descriptive (e.g., case reports, cross-sectional) and analytical (e.g., cohort, case-control), focus on observing relationships between exposures and outcomes without intervention. In contrast, experimental studies, such as randomized controlled trials (RCTs), involve the researcher actively manipulating exposures or treatments to assess their effects on outcomes. Each type provides valuable insights into disease patterns and causal relationships in populations.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3580103e",
      "audio": ""
    },
    {
      "text": "Which of the following is a water-based disease?",
      "options": [
        {
          "label": "A",
          "text": "HAV",
          "correct": true
        },
        {
          "label": "B",
          "text": "HBV",
          "correct": false
        },
        {
          "label": "C",
          "text": "HCV",
          "correct": false
        },
        {
          "label": "D",
          "text": "HDV",
          "correct": false
        }
      ],
      "correct_answer": "A. HAV",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>HAV Hepatitis A Virus (HAV) is a waterborne disease transmitted through contaminated water or food, often linked to poor sanitation. It causes acute liver infection and is common in areas with inadequate hygiene.</p>\n<p><strong>Highyeild:</strong></p><p>Hepatitis A is an acute liver infection caused by the Hepatitis A Virus (HAV), a non-enveloped RNA virus primarily transmitted via the fecal-oral route. It often spreads through consumption of contaminated water or food, especially in areas with poor sanitation and hygiene. The incubation period is approximately 15\u201350 days, after which symptoms such as fever, fatigue, jaundice, nausea, vomiting, abdominal pain, dark urine, and pale stools may appear. The disease is usually self-limiting and does not progress to chronic hepatitis or cirrhosis. Severe cases, including fulminant hepatitis, are rare but more common in older adults or individuals with pre-existing liver disease. Diagnosis is made through the detection of IgM anti-HAV antibodies in the blood. Prevention includes improved sanitation, hand hygiene, and vaccination, which provides long-term protection and is recommended for travelers to endemic regions, children, and individuals at high risk. Treatment is supportive, focusing on symptom relief and maintaining hydration, as there is no specific antiviral therapy for HAV.</p>\n<p><strong>Random:</strong></p><p>Explanation for other options: - Option: B. Hepatitis B Virus (HBV) : Spread through blood, sexual contact, or perinatal transmission, not waterborne. Option: C. Hepatitis C Virus (HCV) : Transmitted via blood-to-blood contact, often through sharing needles or unsafe medical practices. Option: D. Hepatitis D Virus (HDV) : Requires HBV for replication and is transmitted similarly to HBV, not waterborne.</p>\n<p><strong>Extraedge:</strong></p><p>Water related disease: Classification Transmission route Example of diseases transmitted Waterborne Through ingestion of pathogens in drinking water Diarrhoea diseases Enteric fevers, such as typhoid Hepatitis A Water-washed Through incidental ingestion of pathogens in the course of other activities; results from having insufficient water for bathing and hygiene Diarrhoea diseases Trachoma Scabies Water-based Through an aquatic invertebrate host; results from repeated physical contact with contaminated water Guinea worm Schistosomiasis Water-related insect vector Through an insect vector that breeds in or near water Malaria (parasite) and Yellow fever (virus)</p>\n<p><strong>Table:</strong></p><p>#MANTRA Hepatitis A, B, C, and D: Virus Virus Type Transmission Incubation Period Chronic Infection Severity Diagnosis Vaccine Availability Treatment Hepatitis A Virus (HAV) RNA (Picornavirus) Fecal-oral (contaminated food/water) 15\u201350 days No Usually mild, self-limiting IgM anti-HAV antibodies Yes Supportive Hepatitis B Virus (HBV) DNA (Hepadnavirus) Blood, sexual contact, perinatal 30\u2013180 days Yes (5\u201310%) Acute or chronic, can lead to cirrhosis or HCC HBsAg, anti-HBc, anti-HBs Yes Antivirals for chronic cases Hepatitis C Virus (HCV) RNA (Flavivirus) Blood-to-blood contact 14\u2013180 days Yes (70\u201385%) Chronic, high risk of cirrhosis and HCC Anti-HCV antibodies, HCV RNA No Direct-acting antivirals (DAAs) Hepatitis D Virus (HDV) RNA (Delta virus) Requires HBV co-infection 30\u201360 days (with HBV) Yes (only with HBV co-infection) Severe when co-infected with HBV Anti-HDV antibodies, HDV RNA No (prevented with HBV vaccine) Manage HBV; no specific antivirals</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8c4d2f8a",
      "audio": ""
    },
    {
      "text": "Malaria detection in the field is done by which of the following?",
      "options": [
        {
          "label": "A",
          "text": "Thick smear",
          "correct": false
        },
        {
          "label": "B",
          "text": "Thin smear",
          "correct": false
        },
        {
          "label": "C",
          "text": "HRP2 antigen / Rapid diagnostic test",
          "correct": true
        },
        {
          "label": "D",
          "text": "Quantitative Buffy coat",
          "correct": false
        }
      ],
      "correct_answer": "C. HRP2 antigen / Rapid diagnostic test",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>HRP2 antigen / Rapid diagnostic test HRP2 antigen / Rapid Diagnostic Test (RDT) is commonly used in field settings for quick malaria detection. It detects antigens produced by Plasmodium species, especially P. falciparum. It is simple, requires minimal training, and provides results within 15\u201320 minutes.</p>\n<p><strong>Highyeild:</strong></p><p>Malaria detection involves a variety of diagnostic techniques, each suited to different settings and purposes. Thick and thin blood smears, examined under a microscope, are the gold standard for malaria diagnosis. The thick smear is highly sensitive and used to detect the presence of parasites, particularly in cases of low parasitemia, while the thin smear is utilized for species identification and determining the parasite load. Both require skilled personnel and laboratory infrastructure, making them less practical in remote or field conditions. Rapid Diagnostic Tests (RDTs) have revolutionized malaria diagnosis, especially in field settings. These tests detect specific antigens produced by Plasmodium species, such as the HRP2 antigen for P. falciparum. RDTs are simple, require minimal training, and provide results within 15\u201320 minutes, making them the method of choice for quick, point-of-care diagnosis in resource-limited areas. The Quantitative Buffy Coat (QBC) method uses fluorescence microscopy to detect malaria parasites. Although highly sensitive, it requires specialized equipment and is less commonly used in field settings due to cost and complexity. Emerging techniques like PCR offer high sensitivity and specificity but are largely restricted to research and reference laboratories due to their technical and resource-intensive nature.</p>\n<p><strong>Random:</strong></p><p>Explanation for other options: - Option: A. Thick smear: While sensitive and useful for detecting low parasitemia, it requires skilled microscopy and more time, making it less ideal for field settings. Option: B. Thin smear: Used for species identification and quantifying parasitemia but also requires expertise and proper laboratory settings. Option: D. Quantitative Buffy Coat (QBC): A specialized technique for malaria detection but involves expensive equipment and is not practical for field use.</p>\n<p><strong>Extraedge:</strong></p><p>Diseases Under NVBDCP Main Vector Chikungunya fever Aedes aegypti Malaria Female Anopheles Filariasis Culex quinque fasciatus (C. fatigans) Dengue Aedes aegypti Kala Azar Sandfly (Phlebotomus) Japanese Encephalitis Culex tri Taeniorhynchus</p>\n<p><strong>Table:</strong></p><p>#MANTRA Malaria Diagnosis in Field Setting:</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ea501dd3",
      "audio": ""
    },
    {
      "text": "Which of the following is not used in uncomplicated Falciparum Malaria management?",
      "options": [
        {
          "label": "A",
          "text": "Artesunate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Artemether",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chloroquine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Primaquine",
          "correct": false
        }
      ],
      "correct_answer": "C. Chloroquine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Chloroquine In uncomplicated P. falciparum malaria, treatment involves Artemisinin-based Combination Therapies (ACTs) such as Artesunate or Artemether combined with a partner drug, which are highly effective. Primaquine is added as a single-dose adjunct to eliminate gametocytes and prevent transmission. Chloroquine is not used due to widespread resistance in P. falciparum, though it remains effective for P. vivax and P. ovale in certain regions.</p>\n<p><strong>Highyeild:</strong></p><p>Management of uncomplicated Plasmodium falciparum malaria involves the use of Artemisinin-based Combination Therapies (ACTs), which are the first-line treatment recommended by the World Health Organization (WHO). ACTs combine an artemisinin derivative (such as Artesunate or Artemether) with a partner drug, such as lumefantrine or amodiaquine. The artemisinin derivatives quickly reduce the parasite load, while the partner drug ensures complete clearance and helps prevent resistance. The combination approach is designed to maximize efficacy, reduce relapse rates, and minimize the development of drug resistance. For severe or complicated cases , intravenous artesunate is used for initial treatment, followed by an oral ACT once the patient\u2019s condition stabilizes. This approach is critical in preventing mortality, as severe P. falciparum malaria can lead to complications such as cerebral malaria, organ failure, and shock. In addition to ACTs, Primaquine is often administered to eliminate the gametocytes of P. falciparum, thereby reducing the transmission of the parasite to mosquitoes. It is usually given as a single dose at the end of the treatment regimen. However, it is important to note that Primaquine is not used in patients with G6PD deficiency, as it can cause hemolysis. Chloroquine is generally not used in the treatment of P. falciparum malaria anymore, due to widespread resistance. While it is still effective against other species like Plasmodium vivax, it does not work against P. falciparum in areas where resistance has developed. Other supportive measures, such as fluid management, are important, particularly in severe cases. Antipyretics can be used to manage fever, and transfusions may be required in cases of severe anemia or hemolysis.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Artesunate: This is part of Artemisinin-based Combination Therapy (ACT) and is highly effective for treating uncomplicated falciparum malaria. Option: B. Artemether: Another artemisinin derivative, commonly used in ACTs, and is an essential drug for falciparum management. Option: D. Primaquine: Used as a single dose in falciparum to clear gametocytes and prevent disease transmission, making it a standard adjunct therapy.</p>\n<p><strong>Extraedge:</strong></p><p>Malaria treatment in Pregnancy:</p>\n<p><strong>Table:</strong></p><p>#MANTRA Malaria Treatment: Type of Malaria Treatment \u25cf       P. vivax \u25cf       Chloroquine 3 days + Primaquine 0.25 mg/kg 14 days \u25cf       P. falciparum (Rest of India) \u25cf       Artesunate (ASP) 4 mg/kg + Primaquine (PQ) 0.75 mg/kg on day 2 \u25cf       P. falciparum (Northeastern States) \u25cf       Artemether-Lumefantrine (AL) + Primaquine (PQ) 0.75 mg/kg on day 2 \u25cf       Mixed Infection \u25cf       Artemisinin-based Combination Therapy (ACT) as for P. falciparum + Primaquine (PQ) 14 days</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4148997d",
      "audio": ""
    },
    {
      "text": "All of the following help to prevent spread of COVID 19 except:",
      "options": [
        {
          "label": "A",
          "text": "Cough etiquette",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mask",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ivermectin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Vaccine",
          "correct": false
        }
      ],
      "correct_answer": "C. Ivermectin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Ivermectin Ivermectin has been studied for COVID-19 treatment, but its use for prevention or as an effective treatment is not supported by sufficient evidence. The WHO and other health authorities have not endorsed it for COVID-19 prevention.</p>\n<p><strong>Highyeild:</strong></p><p>COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus, which was first identified in Wuhan, China, in December 2019. It quickly spread globally, leading to the COVID-19 pandemic. The virus primarily spreads through respiratory droplets when an infected person coughs, sneezes, or talks. It can also spread via contaminated surfaces, though airborne transmission is also a possibility in enclosed spaces with poor ventilation. COVID-19 symptoms range from mild to severe, including fever, cough, shortness of breath, fatigue, and loss of taste or smell. Severe cases can lead to pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, and death, particularly in older adults or those with underlying health conditions such as heart disease, diabetes, and obesity. Preventive measures to curb the spread of COVID-19 include wearing masks, practicing physical distancing, frequent handwashing, and vaccination. The development of vaccines, such as the mRNA-based Pfizer-BioNTech and Moderna vaccines, and the adenovirus-based Johnson & Johnson and Oxford-AstraZeneca vaccines, has played a pivotal role in reducing the severity of infections and transmission. Booster doses are recommended for enhanced immunity, especially as new variants of the virus emerge. Treatment for COVID-19 varies depending on the severity of symptoms. Mild cases are managed with supportive care, including rest, hydration, and over-the-counter medications. For severe cases, treatments may include antivirals like remdesivir, monoclonal antibodies, corticosteroids (like dexamethasone), and oxygen therapy. In some cases, mechanical ventilation or intensive care may be necessary.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Cough etiquette includes covering the mouth and nose when coughing or sneezing, helps prevent respiratory droplets from spreading and reducing transmission. Option: B. Masks are essential in reducing the spread of COVID-19 by trapping respiratory droplets that carry the virus, especially in crowded or enclosed spaces. Option: D. Vaccines have proven effective in preventing COVID-19 infection and reducing the severity of disease, thus playing a major role in preventing the spread.</p>\n<p><strong>Table:</strong></p><p>#MANTRA COVID 19 Management Guidelines:</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "33b4bba8",
      "audio": ""
    },
    {
      "text": "Dr. Sarah made a presentation on Infectious diseases. She spoke about prevention and treatment of Zika virus. Which of the following is true with respect to the prevention of Zika virus?",
      "options": [
        {
          "label": "A",
          "text": "Symptomatic treatment with NSAIDs",
          "correct": false
        },
        {
          "label": "B",
          "text": "Purified, inactivated FDA approved vaccine is found to be helpful in prevention",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sexual abstinence, using condoms, delaying pregnancy is helpful in controlling the disease",
          "correct": true
        },
        {
          "label": "D",
          "text": "Immunoglobulin and plasmapheresis is used in the treatment of Zika",
          "correct": false
        }
      ],
      "correct_answer": "C. Sexual abstinence, using condoms, delaying pregnancy is helpful in controlling the disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Sexual abstinence, using condoms, delaying pregnancy is helpful in controlling the disease The correct answer is Sexual abstinence, using condoms, delaying pregnancy. Zika virus can be transmitted sexually, and preventing pregnancy, using condoms, and practicing sexual abstinence are key strategies in controlling the disease. There is currently no FDA-approved vaccine, and NSAIDs are avoided due to potential complications. Immunoglobulin and plasmapheresis are not used in Zika virus treatment.</p>\n<p><strong>Highyeild:</strong></p><p>Zika virus is a mosquito-borne illness primarily transmitted by the Aedes species, particularly Aedes aegypti and Aedes albopictus. The virus was first identified in the Zika Forest of Uganda in 1947, but it gained significant global attention during outbreaks in the Pacific Islands, and later in the Americas, particularly during the 2015-2016 outbreak in Brazil. Zika virus is generally mild, with symptoms including fever, rash, joint pain, and conjunctivitis. However, the virus poses serious risks, especially to pregnant women, as it has been linked to microcephaly (a birth defect where babies are born with abnormally small heads) and other brain defects in infants. Zika is also associated with Guillain-Barr\u00e9 syndrome (GBS), a condition in which the body's immune system attacks its own nerves, leading to muscle weakness and paralysis. Transmission occurs primarily through mosquito bites, but the virus can also be spread through sexual contact, blood transfusions, and from mother to fetus during pregnancy. There is no specific antiviral treatment for Zika, and care is typically supportive, focusing on relieving symptoms such as fever and pain. Prevention is crucial and includes avoiding mosquito bites through the use of insect repellent, wearing protective clothing, and eliminating mosquito breeding sites. Since Zika can be sexually transmitted, using condoms and practicing sexual abstinence during and after infection is recommended.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Symptomatic treatment with NSAIDs : NSAIDs are avoided in Zika virus infection due to the risk of bleeding, especially in co-infections like dengue, where bleeding complications are common. Option: B. Purified, inactivated FDA-approved vaccine : Currently, no FDA-approved vaccine exists for Zika virus, so this option is incorrect. Option: D. Immunoglobulin and plasmapheresis : These treatments are not used for Zika virus. The main management is supportive care, including hydration and pain relief, not immunoglobulins or plasmapheresis.</p>\n<p><strong>Extraedge:</strong></p><p>The Indian Council of Medical Research (ICMR) has partnered with Hyderabad-based Indian Immunologicals to develop a vaccine for Zika virus , a mosquito-borne viral infection. This collaboration aims to address the growing concern of Zika outbreaks, especially due to its potential impact on pregnant women and the associated risk of microcephaly in newborns.</p>\n<p><strong>Table:</strong></p><p>#MANTRA Virus Transmission Symptoms Incubation Period Complications Treatment Vaccine Zika Virus Primarily by mosquitoes (Aedes species), also sexual transmission and from mother to fetus. Mild, often asymptomatic: fever, rash, joint pain, conjunctivitis. 3-14 days Microcephaly in newborns if pregnant women are infected, Guillain-Barr\u00e9 syndrome. Supportive care, no specific antiviral treatment. No FDA-approved vaccine (research ongoing). Ebola Virus Direct contact with body fluids of infected individuals (blood, saliva, vomit). Sudden onset of fever, vomiting, diarrhea, hemorrhagic symptoms (bleeding), high mortality. 2-21 days Hemorrhagic fever, multi-organ failure, shock, high mortality rate (up to 90%). Supportive care, experimental treatments and vaccines (e.g., rVSV-ZEBOV vaccine). Yes, rVSV-ZEBOV vaccine approved for prevention. Nipah Virus Bat-to-human transmission, animal-to-human via infected animals (pigs, bats), human-to-human via respiratory droplets. Fever, headache, dizziness, respiratory distress, seizures, encephalitis. 4-14 days Encephalitis, respiratory distress, can lead to coma and death. Supportive care, antivirals like ribavirin may be used in some cases. No FDA-approved vaccine.</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7aa8e672",
      "audio": ""
    },
    {
      "text": "Which of the following vaccines is not recommended after 65 years?",
      "options": [
        {
          "label": "A",
          "text": "Influenza",
          "correct": false
        },
        {
          "label": "B",
          "text": "Herpes Zoster",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pneumococcal",
          "correct": false
        },
        {
          "label": "D",
          "text": "Human papillomavirus",
          "correct": true
        }
      ],
      "correct_answer": "D. Human papillomavirus",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Solution:</strong></p><p>Human papillomavirus The Human papillomavirus (HPV) vaccine is not recommended for individuals over 65, as it is primarily targeted for those up to age 26, with limited use up to age 45 based on individual risk.</p>\n<p><strong>Highyeild:</strong></p><p>Human Papillomavirus (HPV) is a diverse group of more than 200 related viruses, classified into low-risk and high-risk types. Low-risk types can cause benign conditions such as genital warts, while high-risk types, particularly HPV types 16, 18, 31, and 45, are responsible for the majority of cancers, including cervical, anal, vaginal, vulvar, penile, and oropharyngeal cancers. HPV is primarily transmitted through direct skin-to-skin contact, most commonly during sexual activity. While many HPV infections are asymptomatic and are cleared by the immune system within 1\u20132 years, persistent infection with high-risk HPV strains can lead to cellular changes and, if untreated, progress to cancer over time. Cervical cancer is the most common cancer associated with HPV, with types 16 and 18 responsible for approximately 70% of all cases. Preventative measures include vaccination with vaccines like Gardasil and CERVAVAC, which protect against the high-risk HPV types that cause cancer, as well as certain low-risk types that cause genital warts. The HPV vaccine is recommended for both males and females, typically administered at ages 9 to 14, though catch-up vaccinations can occur up to age 26, and in some cases up to 45, based on individual risk factors.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Influenza vaccine : Recommended for individuals over 65 to protect against seasonal flu, as older adults are at higher risk for severe complications. Option: B. Herpes Zoster vaccine : Recommended for those aged 50 and above, including individuals over 65, to prevent shingles and its complications, which are more common in older adults. Option: C. Pneumococcal vaccine : Recommended for those over 65 to protect against pneumonia caused by pneumococcal bacteria, which can cause severe illness in older adults.</p>\n<p><strong>Extraedge:</strong></p><p>CERVAVAC is an Indian-made vaccine developed by the Serum Institute of India to protect against Human Papillomavirus (HPV), a leading cause of cervical cancer. It is designed to prevent infection from the HPV types 16 and 18, which are responsible for the majority of cervical cancer cases. Approved by the Drugs Controller General of India (DCGI), CERVAVAC offers an affordable and accessible alternative to existing HPV vaccines, helping to improve cancer prevention efforts, especially in low- and middle-income countries.</p>\n<p><strong>Table:</strong></p><p>#MANTRA HPV VACCINATION SCHEDULE IN INDIA AGE GROUP WHO IS IT FOR VACCINE NAME SCHEDULE Age 9 to 14 Female Bivalent (HPV2) or Quadrivalent (HPV4) Two doses six months apart from the date of first dose Age 9 to 26 Female Nonavalent (HPV9) Three doses required within six month period \u25cf       First dose initial date \u25cf       Second dose two months after the first dose \u25cf       Third dose, six months after the first dose Age 9 to 15 Male Nonavalent (HPV9) Three doses required within six month period \u25cf       First dose: initial date \u25cf       Second dose: two months after first dose \u25cf       Third dose six months after</p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c41f8810",
      "audio": ""
    }
  ]
}